Oral cancer: Current and future diagnostic techniques

Crispian Scully, CBE, PhD, MD, MDS, MRCS, FDSRCS, FDSRCPS, FFDRCSI, FHEA, FRCPath, FMedSci, FFDRCSI, FDSRCS, FDSRCSE
José V. Bagan, DDS, PhD, MD, Colin Hopper, MD, FRCS(Ed), FDSRCS & Joel B. Epstein, DMD, MSD, FRCD(C), FDSRCS

ABSTRACT: Oral cancer is among the 10 most common cancers worldwide, and is especially seen in disadvantaged elderly males. Early detection and prompt treatment offer the best chance for cure. As patient awareness regarding the danger of oral cancer increases, the demand for “screening” is expected to increase. The signs and symptoms of oral cancer often resemble less serious conditions more commonly found and similarly usually presenting as a lump, red or white patch or ulcer. If any such lesion does not heal within 3 weeks, a malignancy or some other serious disorder must be excluded and a biopsy may be indicated. Dental health care workers have a duty to detect benign and potentially malignant oral lesions such as oral cancer and are generally the best trained health care professionals in this field. Prompt referral to an appropriate specialist allows for the best management but, if this is not feasible, the dental practitioner should take the biopsy which should be sent to an oral/head and neck pathologist for histological evaluation. (Am J Dent 2008;21:199-209).

Clinical significance: Early detection and prompt treatment offer the best hope to the patient with oral cancer, providing the best chance of cure. As patient awareness regarding the danger of oral cancer increases, the demand for “screening” is expected to increase.

Introduction

Most cancers of the oral cavity are oral squamous cell carcinomas (OSCC), and tobacco, alcohol and betel use use the main risk factors for these and many potentially malignant lesions (PML). Early diagnosis of PML can reduce mortality. Early diagnosis of OSCC can speed proceeding to treatment and can improve the prognosis. This requires patients to seek an oral and dental examination at an early stage.

Conventional oral examination (COE) is the standard method of revealing PML and OSCC, confirming the clinical suspicion by biopsy and histopathological examination. Histopathology has for many years been the gold standard in the diagnosis of OSCC; however, it is a rather slow process, requiring several days to fix, embed and stain the biopsy specimen before results can be available. It is subject to interpretation of pathologists, and although it can detect cellular changes, it can only detect molecular changes if special techniques are employed.

This review outlines the signs and symptoms of oral cancer and potentially malignant lesions, which often resemble less serious conditions more commonly found in the mouth and discusses the available and developing adjuncts for detection and diagnosis of oral cancer. All such techniques require more multicenter cross-sectional/longitudinal controlled trials in high risk patients and low risk populations with histologic outcomes.

Potentially malignant oral lesions

OSCC may be preceded by clinically evident PMLs, particularly erythroplakia (erythroplasia) (Fig. 2) and some leukoplakias (Fig. 3). Erythroplasia is rare, and presents as a velvety red plaque. At least 85% of cases show frank malignancy or severe dysplasia and carcinomas are seen 17 times more frequently in erythroplasia than in leukoplakia even though leukoplakias are far more common. Leukoplakia is the most common potentially malignant oral lesion and may also be potentially malignant, transformation ranging from 3-33% over 10 years. The higher transformation rates are seen particularly where there are red lesions admixed, as in speckled leukoplakia, and in proliferative verrucous leukoplakia (Fig. 4); sublingual leukoplakia (Fig. 5); candidal leukoplakia (Fig. 6); syphilitic leukoplakia (exceptionally rare now). Not all leukoplakias are potentially malignant; for example, hairy leukoplakia seen mainly in immunosuppressed people, has no known malignant potential. The other potentially malignant lesions or conditions may include actinic cheilitis, oral submucous fibrosis and some lichen planus (Table 1). However, most other oral white lesions, such as homogeneous leukoplakias, have very low potential for malignant transformation.

The clinical dilemma is to determine the malignant potential of an oral PML and, apart from clinical appearance and location, epithelial dysplasia has conventionally been the marker most used. The limitations of this are discussed below.

Occult primary oral cancers

It was recognized more than half a century ago that oral cancers may have a multicentric origin. Molecular changes indicative of malignant potential do not necessarily produce clinically evident lesions and may be widespread, including outside the clinically identifiable lesion; indeed, dysplastic or malignant changes may be detectable in clinically normal mucosa at sites far removed from an OSCC. It is not surprising therefore, that second primary tumors are seen in up to about one-third of patients within a 5-year period.

Clinical diagnosis of OSCC

Since there may be widespread dysplastic mucosa (“field change”) or a second primary neoplasm, the whole oral mucosa should be examined often, along with examination of...
Fig. 1. Carcinoma of tongue.

Fig. 2. Erythroplasia.

Fig. 3. Leukoplakia.

Fig. 4. Proliferative verrucous leukoplakia.

Fig. 5. Sublingual keratosis.

Fig. 6. Candidal leukoplakia.

Table 1. Potentially malignant oral lesions and conditions.

<table>
<thead>
<tr>
<th>Lesion</th>
<th>Known etiological factors</th>
<th>Main clinical features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erythroplasia</td>
<td>Tobacco/alcohol</td>
<td>Red plaque</td>
</tr>
<tr>
<td>Actinic cheilitis</td>
<td>Sunlight</td>
<td>White plaque/erosions</td>
</tr>
<tr>
<td>Chronic candidosis (candidal leukoplakia)</td>
<td>Candida albicans</td>
<td>White or speckled white and red plaque</td>
</tr>
<tr>
<td>Dyskeratosis congenita</td>
<td>Genetic</td>
<td>White plaques</td>
</tr>
<tr>
<td>Leukoplakia (non-homogeneous)</td>
<td>Tobacco/alcohol</td>
<td>Speckled white and red plaque or nodular plaque</td>
</tr>
<tr>
<td>Proliferative verrucous leukoplakia</td>
<td>Human papillomavirus (HPV); most frequent no history of tobacco/alcohol</td>
<td>White or speckled white and red or nodular plaque</td>
</tr>
<tr>
<td>Sublingual keratosis</td>
<td>Tobacco/alcohol</td>
<td>White plaque</td>
</tr>
<tr>
<td>Submucous fibrosis</td>
<td>Areca nut</td>
<td>Immobile pale mucosa</td>
</tr>
<tr>
<td>Syphilitic leukoplakia</td>
<td>Treponema pallidum</td>
<td>White plaque</td>
</tr>
<tr>
<td>Atypia in immunocompromised patients</td>
<td>HPV</td>
<td>White or speckled white and red plaque</td>
</tr>
<tr>
<td>Leukoplakia (homogeneous)</td>
<td>Friction/tobacco/alcohol</td>
<td>White plaque</td>
</tr>
<tr>
<td>Discoid lupus erythematous</td>
<td>Autoimmune</td>
<td>White plaque/erosions</td>
</tr>
<tr>
<td>Lichen planus</td>
<td>Idiopathic</td>
<td>White plaques</td>
</tr>
<tr>
<td>Fanconi syndrome</td>
<td>Genetic; anemia</td>
<td>White plaques</td>
</tr>
<tr>
<td>Paterson-Kelly-Brown syndrome</td>
<td>Iron deficiency</td>
<td>Post-cricoid web</td>
</tr>
</tbody>
</table>

the rest of the upper aerodigestive tract, and the cervical lymph nodes must always be carefully examined by palpation. Particular attention should be given to high incidence sites for OSCC, such as the lip (Fig. 7), floor of mouth, lingual vestibule and side of tongue.

Many OSCCs can be detected visually by a trained examiner\(^\text{16}\) but early OSCC can be asymptomatic, and may appear innocuous, and can be overlooked\(^\text{17}\) especially if the examination is not thorough. A number of studies have suggested not only that dentists can screen patients, but so can trained auxiliaries, although the evidence for effectiveness of screening remains controversial.\(^\text{18,20}\) Nevertheless, some experts
suggest that even highly trained health care professionals with broad experience cannot adequately identify all PMLs and early stage OSCC by visual inspection alone.21

Classic features of oral malignancy include ulceration, nodularity, induration and fixation8,22 and cancer must be suspected especially when there is a single oral lesion persisting for more than 3 weeks. OSCC may present variously as (Table 2):

• an indurated lump/ulcer i.e. a firm infiltration beneath the mucosa (Fig. 8)
• a granular ulcer with fissuring or raised exophytic margins
• a white or mixed white and red lesion
• a red lesion (erythroplasia)
• a lump sometimes with abnormal supplying blood vessels
• a non-healing extraction socket
• a lump fixed to deeper tissues or to overlying skin or mucosa
• other features (as shown in Table 2)
• cervical lymph node enlargement, especially if there is hardness in a lymph node or fixation. Enlarged nodes in a patient with oral carcinoma may be caused by infection, reactive hyperplasia secondary to the tumor, or metastatic disease. Occasionally (about 5%) a cervical lymph node enlargement is detected in the absence of any obvious primary tumor, where the most likely site for the primary in order of predilection is the tongue base, tonsil or nasopharynx.

However, the recognized classic features of OSCC (Table 1), such as ulceration, induration, elevation, bleeding, and cervical lymphadenopathy are features of advanced disease, not early stage disease,23 and there is often a substantial delay in biopsy even when oral lesions display characteristics of frank cancers.24,25 Biopsy needs to supplement clinical diagnosis in order to establish or exclude, malignant disease and yet in reality, few leukoplakias (the most common PML), are ever biopsied.26 In addition, OSCC, even if clinically visible, can resemble oral PML and some common benign oral lesions.

Thus, the reliable differentiation of malignant lesions from benign lesions by clinical inspection alone is unreliable.22,27 Also, malignant transformation of potentially malignant lesions cannot be accurately predicted based solely upon clinical characteristics.

The only method currently available to reliably determine the diagnosis and give an indication of prognosis is the laboratory histopathological examination of a tissue sample since it is accepted that dysplasia may precede malignant change.28 Therefore it is mandatory to biopsy any persistent mucosal lesion where there is not absolute confidence that the diagnosis is of a benign lesion. There should be a high index of suspicion, especially of a solitary lesion present for over 3 weeks. In practice therefore, all ulcerated, red, white or mixed solitary oral lesions persisting 3 weeks or more require biopsy evaluation.

Current diagnostic techniques: Potential and limitations

Early diagnosis and treatment are the goals.29,30 Since the COE has undetermined sensitivity and specificity,31 there is a need for more accurate diagnostic tools that can detect early lesions and determine either the potentially malignant or the benign nature of lesions. The need is great considering the large number of oral lesions encountered by dentists performing oral cancer screening, which amounts to 5-15% of screened patients.32-34

Currently available and developing tools are shown in Table 3. The available technologies are discussed here, with a synopsis of more embryonic emerging technologies later.

Biopsy and histopathological examination

The biopsy should be sufficiently large to include suspect and apparently normal tissue to give the pathologist a chance to make a diagnosis and not to have to request a further specimen. Since red rather than white areas are most likely to show any dysplasia present in the lesion, a biopsy should include the former.
Most biopsy wounds heal rapidly within days and it is important to ensure sufficient sampling to allow diagnosis and to take at least one ample specimen (Fig. 9). Some clinicians always take several biopsies at the first visit in order to avoid the delay and aggravation resulting from a negative pathology report in a patient who is strongly suspected as suffering from a malignant neoplasm. An excisional biopsy should be avoided since this will not remove a sufficient margin of tissue if the lesion is malignant and may limit the surgeon or radiotherapist, clinical evidence of the site, and character of the lesion.

Carcinoma is diagnosed when histopathological examination shows there is:

- dysplasia extending through the full thickness of the epithelium (severe dysplasia) and with,
- extension of the rete pegs into the underlying lamina propria, i.e. invasion across the basement membrane.

Progression of a PML to OSCC is as high as 36% when moderate or severe epithelial dysplasia is present and occurs in up to 50% in lesions with severe dysplasia. However, the histological findings of dysplasia indicate no more than that a potential risk of malignant change, and cannot be used for confident prediction of malignant change in any individual case. The prognostic value of histopathological features related to a primary OSCC tumor and the cervical lymph nodes has been reviewed.35 Emphasis is given to practical aspects of the histopathological assessment, potential inaccuracies, the importance of the partnership between surgeon and pathologist, the need for standardization throughout the histopathological assessment, and the value of accurate documentation of findings.

Furthermore, even histological examination of a specimen is fraught with potential pitfalls and is subjective. A major problem in PML is to ensure that the biopsy is taken of the area most likely to contain the greatest number of cellular changes suggestive of premalignancy (dysplasia): to this end, red rather than white areas should be selected for biopsy. Vital staining may facilitate this (see below).

False negative results are still occasionally possible from incisional biopsy and, even where dysplasia has been excluded in a leukoplakia by incisional biopsy, studies have shown that the lesions, if wholly excised, may prove to contain OSCC in up to 10%.36 This is not surprising, given that molecular changes consistent with early malignant changes can be scattered through and beyond a potentially malignant clinical lesion.37,38 Furthermore, pathologists have been shown to vary in their opinions, and even the same pathologist may offer a different opinion on different occasions if faced with exactly the same specimen.39-42

In light of the above, if the pathology report denies malignancy, and yet clinically this is suspected, then discussion with the pathologist and a re-biopsy are invariably indicated. However, not only is conventional histopathology not unequivocally reliable but the goal should surely be to detect not only malignant and potentially malignant clinical lesions, but ideally to reveal epithelial molecular or DNA changes indicative of early carcinogenesis even where clinical lesions are not seen. Therefore there has been a desire to develop new diagnostic methods that yield greater information about PML, and tumors including their prognosis43 and this is where biomarkers (molecular markers) could play an important role in eliciting changes undetectable by examination of conventional hematoxylin and eosin stained sections.

**Vital staining**

Various attempts to clinically highlight probable dysplastic areas before biopsy have, unfortunately, not proven to be absolutely reliable but may be of some help where there is widespread "field change" such as seen in patients at high risk for OSCC. Toluidine blue (TB) staining is a simple and inexpensive diagnostic tool that uses a blue dye to highlight abnormal areas of mucosa. TB is a basic metachromatic nuclear stain which stains nuclear material of malignant lesions and PML but not normal mucosa, used by (a) the patient rinsing the mouth with 1% acetic acid for 20 seconds followed by a similar rinse with water twice for 20 seconds; (b) rinsing the mouth with 5-10 cc. 1% toluidine blue solution; and (c) rinsing with 1% acetic acid solution (5 oz.) for about 1 minute followed by a water rinse.

In the highest risk population, prior upper autodigestive tract cancer patients, TB has a higher sensitivity to detect carcinoma in situ (CIS) and OSCC when compared to a COE (96.7% and 40%, respectively).44 False positive staining (when lesions stain blue, but no carcinoma is identified after a biopsy is taken) occurred in 8-10% of cases associated with keratotic lesions and the regenerating edges of ulcers and erosions.44 Here, the probability of a false negative finding for invasive OSCC is low and the absolute number of false positive tests is expected to be reduced. The clinical appearance of a dark royal blue stain may be significantly related to the nuclear uptake of TB, compared to pale royal blue staining which may be unrelated to any histological feature.45 Studies assessing TB have shown a sensitivity and specificity ranging from 93.5 to 97.8% and 73.3 to 92.9%, respectively.44,46,47

TB staining may identify high-risk oral PMLs with poor outcome46,50 and positive TB staining may be related to genetic changes [allelic loss or loss of heterozygosity (LOH)] associated with progression to OSCC even in histologically benign lesions and lesions with mild dysplasia.48,49 TB may also help preoperatively; in one reported case of OSCC, there were malignant or pre-malignant cells more than 1 cm away, requiring a resection of a size that would not have been addressed during COE alone,51 though, from the discussion above, it can be seen that even mucosa of a normal appearance might be expected to contain molecular changes of early carcinogenesis.

**Biomarkers**

Since the introduction of molecular techniques such as examination for abnormal protein expression, including tumor suppressor genes (TSGs) and other genetic changes, molecular markers have revealed neoplastic changes in PML (and furthermore may predict involvement of tumor resection margins and lymph nodes, and prognosis).

The most predictive of the molecular markers thus far available and assessed in OSCC development include the TSG p53 protein expression, chromosomal polysomy (DNA ploidy), and changes (termed loss of heterozygosity; LOH) in chromosomes 3p or 9p (probably due to changes in the TSG p16).52

---

The use of such biomarkers as adjuncts to routine histopathological examination may help prognostication and effective management of PMLs but their routine use is still hampered by the cost and complexity of the tests, the lack of facilities in some laboratories, and limited outcome studies to date.

More readily available markers, such as those of cell proliferation (Ki-67 antigen) and apoptosis (Bax, Bcl-2), may also play a diagnostic role. Apoptotic Bcl-2 expression decreases significantly in dysplastic and early invasive lesions and then increases almost to normal tissue level in subsequent stages while Ki-67 expression increases sharply in initial stages of OSCC, but significantly decreases in later stages.

A more aggressive tumor behavior and worse prognosis may also be signified by changes in a range of biomarkers, such as reduced E-cadherin expression, laminin (LN) chain expression, and decreased tumor cell transmembrane proteoglycan syndecan-1.

DNA ploidy

DNA ploidy is the measurement of nuclear DNA content. This may provide a surrogate measure of gross genetic damage and this could act as a surrogate for individual molecular markers.

Normally, a non-dividing somatic cell contains a diploid amount of DNA in 23 pairs or 46 chromosomes. Just before cell division, the DNA is doubled and mitosis; the 23 pairs of chromosomes are evenly distributed to two daughter cells. In somatic cells, if a doubling of the DNA during S-phase occurs without a subsequent cell division, the nucleus will then contain quadruples of the DNA, making the cell tetraploid. Multiple copies of DNA in excess of diploidy is termed polyploidy. If the chromosomes are not uniformly distributed to the daughter cells or if parts of chromosomes become detached, the chromosomal segregation during mitosis is termed unbalanced, a situation termed aneuploidy and commonly observed in many cancers.

DNA ploidy can be measured fairly simply with automated image cytometry of nuclei obtained from routinely processed tissue samples and the expertise is available in many pathology laboratories. However, unfortunately there has been controversy over the ploidy results published from one Norwegian laboratory, which must now be repeated by other workers.

Brush biopsy

The brush biopsy uses a small nylon brush to gather cytology samples then sent for computer scanning and analysis (Oral CDx) to identify and display individual cells. If suspect cells are identified, a pathologist then examines them to determine the final diagnosis and, in samples judged to be cancerous, a printout of the abnormal cells from the computer display and a written pathologist's report are returned to the clinician with the recommendation that a positive result be followed with a conventional incisional biopsy. The technique has proved rather controversial, with concern largely related to the question of false negative results (Table 4).

In the first published study, of 945 patients in USA, the brush biopsy reportedly detected correctly all cases of OSCC, even when dentists did not suspect the presence of cancer from the lesion, but this trial represented a multi-center convenience sample, not all lesions were biopsied and inadequate specimens were excluded from the analysis. In a further US study, brush biopsy results when compared with scalpel biopsy and histology to determine the positive predictive value of an abnormal brush biopsy finding showed that, of 243 patients with abnormal brush biopsies, 93 proved positive either for dysplasia (79) or carcinoma (14), and 150 were negative for either dysplasia or carcinoma, giving the positive predictive value of an abnormal brush biopsy of 38% (93/243). A UK audit which retrospectively determined the sensitivity, specificity and positive and negative predictive values of brush biopsy in the diagnosis of PML in 112 patients showed the sensitivity of detection of dysplasia or OSCC to be 71.4% but the specificity was only 32%. The positive predictive value of an abnormal brush biopsy result was 44.1%, while the negative predictive value was 60%. Review of 115 diagnosed OSCC from another oral pathology service identified four patients who had previously undergone brush biopsy reported to be "negative for epithelial abnormality" (3.5%), further suggesting that false negative reports are possible with the oral brush biopsy. Other workers have confirmed this and also raised concerns about frequent false positive results.

Improved outcomes of brush biopsy may be obtained however, with the addition of molecular techniques. Brush biopsy specimens of 43 oral leukoplakias, 26 OSCCs, and the oral mucosa of four clinically normal volunteers were analyzed.
for TSG p53 mutations, which were found in 57.7% of OSCC, 39.5% of leukoplakias and in 0% controls. A prospective study assessing the diagnostic accuracy of brush biopsies in combination with DNA image cytometry showed a sensitivity of 97.8%, specificity of 100%, positive predictive value 100%, and negative predictive value 98.1%. The same group showed cytology with DNA-cytometry to be a highly sensitive, specific and negative predictive value 98.1%. The same group showed a sensitivity of 97.8%, specificity of 100%, positive predictive value 100%, and negative predictive value 98.1%. The same group showed cytology with DNA-cytometry to be a highly sensitive, specific and negative predictive value 98.1%. The same group showed cytology with DNA-cytometry to be a highly sensitive, specific and negative predictive value 98.1%. The same group showed cytology with DNA-cytometry to be a highly sensitive, specific and negative predictive value 98.1%. The same group showed cytology with DNA-cytometry to be a highly sensitive, specific and negative predictive value 98.1%. The same group showed cytology with DNA-cytometry to be a highly sensitive, specific and negative predictive value 98.1%

The jury is thus still out on the value of the brush biopsy but nevertheless, it should be borne in mind that the results from scalpel biopsies are also not infallible (as discussed above). Indeed, brush biopsy may detect some OSCCs missed on scalpel biopsy. For example, one report of four patients presenting with early OSCC showed the tumors to be detected cytotologically on brush biopsies including DNA-image cytometry as an adjunctive method, in macroscopically suspicious lesions despite initial scalpel biopsies showing no evidence of cancer nor of severe dysplasia. The occurrence of early OSCC was finally confirmed histologically on a repeat scalpel biopsy. Further well-designed studies in non-expert settings and well-designed prospective studies are needed.

Optical systems

Interaction of light with tissues may highlight changes in tissue structure and metabolism. Optical spectroscopy systems to detect changes rely on the fact that the optical spectrum derived from a tissue will contain information about the histological and biochemical characteristics of that tissue. Such optical adjuncts may assist in identification of mucosal lesions including PML and OSCC, assist in biopsy site selection and enhance visibility of surface texture and margins of lesions and may also assist in identification of cellular and molecular abnormalities not visible to the naked eye on routine examination (Figs. 10, 11).

There are a number of optical systems that can yield similar types of information approaching the detail of histopathology and theoretically at least, in a more quantifiable and objective fashion, in real-time, non-invasively and in situ.

Early detection of mucosal lesions can be enhanced by the use of a dilute acetic acid rinse and observation under a chemiluminescent light (ViziLite). Several studies are summarized in Table 5. In one study of 100 patients who presented for dental screening and were examined by COE (under incandescent light) before and after a 1-minute rinse with 1% acetic acid, and then once again using the ViziLite, 57 had clinically diagnosable benign lesions (e.g. linea alba, leukoedema) and 29 clinically undiagnosable lesions initially, but after the acetic acid rinse, six additional diagnosable lesions (linea alba) and three undiagnosable lesions were found. In a multicenter study, increased visibility of lesions visible by COE was reported. In that and other studies, ViziLite revealed occasional lesions not
seen under COE but, occasionally, the converse has been the case, so the jury again is out on the real benefits.

Early detection of mucosal lesions can be enhanced by the use of fluorescence. All tissues have a tendency to glow (fluoresce) in the dark, either spontaneously (auto-fluorescence) or if an external sensitizer is applied to the tissues. The tissue fluoresces due to the presence of fluorescent chromophores (fluorophores) within the cells. Commonly detected fluorophores include nicotinamide adenine dinucleotide hydrogenase, collagen, elastin, flavin adenine dinucleotides, hemoglobin and vascular supply; and oral microbial flora, and they vary in different tissues including different sites in the mouth. Tissue changes can affect the fluorophores and tissue fluorescence, and this may facilitate detection of lesions not detectable with the naked eye under normal incandescent white light.80-91

Fluorescence and changes suggestive of PML or OSCC can already be detected using commercially available photographic techniques (e.g. Storz,6 Pentax,7 Zillix8), but most of these also have relatively low sensitivity and specificity. Preliminary studies using direct visualization (VelScope®) however, have been very encouraging when assessed in patients with OSCC (Table 6).92-94 These early studies must be extended into multicenter controlled trials in patients at and not at risk of OSCC, and with experts and non-expert providers.

Some other potential diagnostic systems are listed in Table 7.

Saliva-based oral cancer diagnostics

Exfoliative cell samples have been used to detect genetic alterations in the oral epithelium of patients at high risk from oral cancer,95 and to detect microsatellite alterations in OSCC.96 The concept of a saliva test to diagnose OSCC is even more appealing.96-103 Promoter hypermethylation patterns of TSG p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase have been identified in the saliva of head and neck cancer patients.104 Forensic science has since shown that saliva can contain a number of messenger ribonucleic acid (mRNA) fragments including salivary specific statherin, histatin 3, and the proline-rich proteins PRB1, PRB2 and PRB3, as well as the ubiquitously expressed spermidine N1 acetyl transferase (SAT), β-actin, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).106 The mRNAs in saliva such as β-actin, SAT and interleukin-8 are relatively stable despite the presence of salivary ribonucleases.97,98,102,106 mRNAs in saliva have been tested in over 300 saliva samples from OSCC patients and healthy people, and the signature was always present in higher levels in the saliva of OSCC patients than in saliva from healthy people, with an overall accuracy rate of about 85%.107 Four salivary mRNAs (OLF/EBF associated zinc finger protein[OAZ], SAT, IIL8, and IIL1b) collectively have a discriminatory power of 91% sensitivity and specificity for OSCC detection.108 This avenue of research is thus clearly most appealing.

CD44, a multistructural and multifunctional cell surface transmembrane glycoprotein molecule involved in cell proliferation, cell differentiation, cell migration, angiogenesis, presentation of cytokines, chemokines, and growth factors to the corresponding receptors, and docking of proteases at the cell membrane, as well as in signaling for cell survival, is also detectable in saliva. CD44 isoforms containing the variant 3 (v3) exon include a growth factor binding site and may be involved in OSCC progression.108,109 Salivary soluble CD44 (solCD44) levels were found significantly raised in head and neck cancer (HNSCC) patients compared with normal controls and detected 79% of mucosally invasive HNSCC using preliminary cutoff points. However, SolCD44 levels did not vary significantly with tumor size, stage, recurrence, history of radiation treatment, or tobacco and alcohol risk factors.110 Further work is awaited as to the utility of CD44 as a cancer marker.

Finally, high salivary counts of Capnocytophaga gingivalis, Prevotella melaninogenica and Streptococcus mitis have been found in patients with OSCC,111 but the suggestion that this could be a reliable diagnostic indicator is difficult to support.

Multicenter studies in large populations at risk of cancer and those at low risk are needed in order to verify the reliability of these saliva-based tests.

Laser-induced fluorescence spectroscopy used to examine OSCC in the hamster buccal pouch model shows increased fluorescence in malignant areas.112

Light-induced fluorescence spectroscopy can distinguish between benign (normal and hyperkeratosis) and dysplasia with a sensitivity of 92% and a specificity of 95%.113 Fluorescence photography detected OSCC with a sensitivity of 91% and specificity of 85%. The relatively low sensitivity and specificity of auto-fluorescence can be markedly improved by adding an exogenous chemical such as aminolevulinic acid (ALA), ap-
plied systemically or topically. Typically in the oral cavity, a mouthwash is applied and the ALA is taken up into the cells and metabolized to protoporphyrin 9 which fluoresces. Interrogation with blue light results in a fluorescence signal which is then captured using a CCD camera which is mosaiced and allows specific measurement of red and green fluorescence. A fluorescent image system associated with gated and allows specific measurement of red and green which is then captured using a CCD camera which is mosaic

Interrogation with blue light results in a fluorescence signal and metabolized to protoporphyrin 9 which fluoresces. Mouthwash is applied and the ALA is taken up into the cells of hemorrhage and this may be detectable by OPS.

Orthogonal polarization spectral (OPS) imaging for the diagnosis of cancer using an algorithm based on nonlinear maximum representation and discrimination feature (MRDF) method. Laser induced fluorescence (LIF) spectroscopy has been developed for the diagnosis of cancer using an algorithm based on nonlinear maximum representation and discrimination feature (MRDF) method.  

Elastic scattering spectroscopy requires light to be fired into tissue in a short burst and the resulting signal is detected by fibers and fed into a spectrometer interfaced with a computer. When light enters the tissue it may be elastically scattered, inelastically scattered, or absorbed. The amount the light scatters depends on nuclear size, shape and orientation i.e. the items that a pathologist examines. In addition, light will be scattered by intracellular organelles and there will also be other changes depending on tissue thickness. Elastic scattering spectroscopy recordings from normal and OSCC tissue may differ and studies on patients with leukoplakia have shown a sensitivity of 72% and specificity of 75% in differentiating cancer and dysplasia from benign lesions.

Raman spectroscopy looks at the vibrational changes in tissue that parallel changes in chemical composition, and is sensitive (for example) to changes in DNA content. Raman spectroscopy is widely used in chemical analysis and is based on “inelastic” light scattering since the detected wavelengths are different from that of the applied light. Fourier transform infrared (FTIR)/Raman spectroscopy has been successfully applied for the diagnosis of OSCC in the hamster cheek pouch model with 100% sensitivity and 55% specificity. 

Photoacoustic imaging relies on the measurement of light-induced acoustic emission. When a laser pulse passes through a tissue, some of the energy is absorbed and generates a sound wave. The image contrast is provided by native light absorbing chromophores such as hemoglobin or other agents such as nanoparticles and dyes. This can be used to look at blood oxygenation and hemoglobin concentration, but it can also be used to image microvascular networks that may be important in early malignancy.

Photon fluorescence uses second harmonic generation (SHG) to detect light emerging from materials at half the wavelength (and twice the energy) of the light entering the material. This multiphoton process only occurs in materials with a particular crystalline structure and optical properties and, in biological systems, only collagen fibrils fulfill these criteria. SHG can be used to detect collagen IV and the lack of it around an invasive carcinoma; detailed structural information at micron scale resolution and indications of pathology can thereby be obtained.

Orthogonal polarization spectral (OPS) imaging for in vivo visualization of the human microcirculation facilitates high resolution images of the oral mucosa. OSCC are characterized by chaotic and dilated vessels accompanied by numerous areas of hemorrhage and this may be detectable by OPS.

Quantum dots are particles of one nanometer in diameter whose action is based on the fluorescence phenomenon. They absorb photons of white light within their core and re-emit nanochromatic light at a specific wavelength, and the re-emitted light is so bright that it is possible to detect it even if only one cell-crystal complex is excited. Quantum dots absorb light over a wide spectrum so it is possible to excite many dots with a single light source, each emitting a different color, thereby allowing detection of multiple markers at the same time.

Optical coherence tomography (OCT), well established in the ophthalmological literature where OCT is used to examine the retina, has the potential to be applied in OSCC diagnosis. OCT combines interferometry with low-coherence light to produce high-resolution tissue imaging and it can detect carcinogenesis in epithelial and sub-epithelial tissues in hamster cheek pouches with an overall sensitivity and specificity of 80%. Newer systems such as Fourrier transformed OCT, a complex interferometric optical tomographic system which offers sub-micrometer resolution, has the potential to give great resolution in a non-invasive way and should yield information about the early changes associated with invasive cancer.

Trimodal spectroscopy uses three independent optical diagnostic techniques (fluorescent spectroscopy, diffuse scattering spectroscopy and elastic scattering spectroscopy) to achieve better results, reaching sensitivity and specificity of 96% in differentiating between normal oral mucosa and dysplasia and OSCC and a sensitivity of 64% and specificity of 90% in distinguishing between dysplasia and OSCC. Trimodal spectroscopy, although having the advantage of being accurate is however, expensive and time-consuming.

Other potential systems include Doppler OCT, nuclear magnetic resonance spectroscopy, chromoendoscopy, narrow band imaging (NBI), immunophotodiagnostic techniques, differential path length spectroscopy, 2 photon fluorescence, 2 harmonic generation, and terahertz imaging.

Summary

All imaging techniques require multicenter controlled trials in high risk patients and low risk populations with histologic outcomes and cross-sectional/longitudinal trials, but adjuncts for detection and diagnosis have the potential to assist in early detection, leading to early diagnosis and improved treatment outcomes.

Dr. Scully is Professor, and Mr. Hopper is Senior Lecturer, UCL Eastman Dental Institute, University College London, London, United Kingdom. Dr. Bagun is Professor, University of Valencia. General University Hospital, Valencia, Spain. Dr. Epstein is Head, Department of Oral Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.

References


